

ASX MEDIA RELEASE

1 March 2023

World leading expert in copper-67 joins Clarity's SAB

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of the world leading expert in copper-67 isotope (Cu-67 or ⁶⁷Cu) production, Jon Stoner, to Clarity's Scientific Advisory Board.

Mr Stoner is the director of the Idaho Accelerator Center (IAC), a research institute of Idaho State University. He has been researching isotope production using linear accelerators for 14 years and pioneered a new process and mechanism for producing therapeutic copper-67 that enables it to be manufactured in the quantities and quality required for clinical development. He has 10 years of experience in production of the copper-67 isotope, and under his leadership the IAC has been shipping copper-67 commercially since 2014, supporting Clarity's Targeted Copper Theranostic (TCT) programs from preclinical through to the clinic where there are now three therapy products in clinical development.

Jon Stoner commented on his appointment, "Clarity is the global leader in TCTs, the next-generation radiopharmaceutical platform based on the "perfect pairing" of copper isotopes, copper-64 and copper-67. TCTs hold significant logistical and manufacturing advantages over current-generation radiopharmaceuticals. In particular, the therapeutic isotope copper-67 does not rely on a limited number of ageing nuclear reactors worldwide where reactor outages and unplanned maintenance remain an issue. The production challenges often cause a ripple effect and mean that vulnerable oncology patients are left waiting for the life-saving treatments. We produce copper-67 in the US on relatively low-cost linear accelerators, and unlike other currently used therapeutic isotopes, such as lutetium-177, the simpler production process for copper-67 allows for high volume and high-purity production that can accommodate the growth of radiopharmaceuticals in large indications, including prostate cancer, in a sustainable and environmentally friendlier manner.

"I am thrilled to be working with Clarity to support the rollout of the therapeutic program with copper-67. We have been working together for approximately 8 years to meet the demands of the growing pipeline and I look forward to furthering our collaboration as the Company moves towards late-stage clinical trials and continues to progress its TCT platform."

Clarity's Executive Chairman, Dr Alan Taylor, commented, "Jon Stoner is the world leader in the production of high purity copper-67 and our relationship has grown over many years as we share the same passion of developing our innovative platform with the goal of better treating children and adults with cancer. The copper-67 Jon has produced has been used in our therapy trials in children with neuroblastoma and adults with meningioma and prostate cancer. Jon's unique experience and expertise have been invaluable in progressing our numerous clinical trials, and we look forward to our continued relationship as we move towards high-volume manufacture of copper-67 and overcome the current limitations in radiopharmaceuticals to address the large oncology market in need of these new therapies with our TCT platform."

Mr Stoner has 3 patents on production of copper-67 and has 11 related publications. He has worked in many technical and business roles in high technology for more than 34 years including Sr. VP and Chief Technology Officer of AMI Semiconductor where he was responsible for world-wide R&D and Intellectual Property, General Manager of the Image Sensor Business Unit and Founder and Managing Partner of C&J Tech Consulting – a company supplying technical evaluation support to Private Equity investors and other clients.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor
Executive Chairman
ataylor@claritypharm.com

Citadel-MAGNUS

Catherine Strong
0406 759 268
cstrong@citadelmagnus.com

This announcement has been authorised for release by the Executive Chairman.